Ostene, a new alkylene oxide copolymer bone hemostatic material, does not inhibit bone healing.
OBJECTIVE
In this study, we investigate the effects of a soft bone hemostatic wax comprised of water-soluble alkylene oxide copolymers (Ostene; Ceremed, Inc., Los Angeles, CA) on bone healing in a rat calvaria defect model. We compared the effects with a control (no hemostatic agent) and bone wax, an insoluble and nonresorbable material commonly used for bone hemostasis.


METHODS
Two bilateral 3-mm circular noncritical-sized defects were made in the calvariae of 30 rats. Alkylene oxide copolymer or bone wax was applied or no hemostatic material was used (control). After 3, 6, and 12 weeks, rats were sacrificed and the calvariae excised. Bone healing, expressed as fractional bone volume (+/- standard error of the mean), was measured by microcomputed tomography.


RESULTS
Immediate hemostasis was achieved equally with bone wax and alkylene oxide copolymer. Bone wax-filled defects remained unchanged at all time points with negligible healing observed. At 3 weeks, no evidence of alkylene oxide copolymer was observed at the application site, with fractional bone volume significantly greater than bone wax-treated defects (0.20 +/- 0.03 versus 0.02 +/- 0.01; P = 0.0003). At 6 and 12-weeks, alkylene oxide copolymer-treated defects continued to show significantly greater healing versus bone wax (0.18 +/- 0.04 versus 0.05 +/- 0.01 and 0.31 +/- 0.04 versus 0.06 +/- 0.02, respectively). At all time points, alkylene oxide copolymer-treated and control defects showed good healing with no significant difference.


CONCLUSIONS
Alkylene oxide copolymer is an effective hemostatic agent that does not inhibit osteogenesis or bone healing.
Magyar
Clara E
CE
Department of Diagnostic and Surgical Sciences, School of Dentistry, University of California, Los Angeles, California 90095, USA. cmagyar@mednet.ucla.edu
Aghaloo
Tara L
TL
Atti
Elisa
E
Tetradis
Sotirios
S
D000818:Animals; D006490:Hemostatics / Q000494:pharmacology*; D023421:Models, Animal; D010012:Osteogenesis / Q000187:drug effects*; D020442:Poloxamer / Q000494:pharmacology*; D051381:Rats; D012886:Skull / Q000187:drug effects* / Q000601:surgery; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*
D006490:Hemostatics; C512681:Ostene; D020442:Poloxamer